Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Egg-free cell line solves an MVA scale-up problem

12 September 2026 · By · Wire by Fusion42

Published

12 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

Transgene and ProBioGen have expanded their partnership by licensing the AGE1.CR.pIX duck-cell suspension line for scalable and reproducible MVA viral vector production, solving key manufacturing constraints faced with egg-based substrates in personalized cancer vaccine production.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now replace egg-based virus production with a duck-cell line that scales for personalised cancer vaccines. This opens a clear path to meeting precise clinical deadlines and batch consistency that you couldn’t access before.

◆ Coverage

1 source · 12 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpersonalized-vaccinesviral-vectorsmanufacturing-scalecell-lineMVAoncology